Abbreviations list
| Abbreviation | Description |
|---|---|
| 10vPCV | 10-valent pneumococcal conjugate vaccine. |
| 13vPCV | 13-valent pneumococcal conjugate vaccine. |
| 15vPCV | 15-valent pneumococcal conjugate vaccine. |
| 20vPCV | 20-valent pneumococcal conjugate vaccine. |
| 23vPPV | 23-valent pneumococcal polysaccharide vaccine |
| 2vHPV | bivalent HPV vaccine |
| 4vHPV | quadrivalent HPV vaccine |
| 4vMenCV | quadrivalent meningococcal conjugate vaccine |
| 4vMenPV | quadrivalent meningococcal polysaccharide vaccine |
| 7vPCV | 7-valent pneumococcal conjugate vaccine |
| ABLV | Australian bat lyssavirus |
| ACT | Australian Capital Territory |
| ADRS | Adverse Drug Reactions System |
| AEFI | adverse event following immunisation |
| AIDS | acquired immunodeficiency syndrome |
| anti-HBc | antibody to hepatitis B core antigen |
| anti-HBe | antibody to hepatitis B e antigen |
| anti-HBs | antibody to hepatitis B surface antigen |
| AOM | acute otitis media |
| ASCIA | Australasian Society of Clinical Immunology and Allergy |
| ATAGI | Australian Technical Advisory Group on Immunisation |
| BCG | bacille Calmette-Guérin |
| CCID50 | cell culture infectious dose 50% |
| CDNA | Communicable Diseases Network Australia |
| CI | confidence interval |
| CIN | cervical intraepithelial neoplasia |
| CRS | congenital rubella syndrome |
| CSF | cerebrospinal fluid |
| DNA | deoxyribonucleic acid |
| DT | diphtheria-tetanus vaccine |
| dT | diphtheria-tetanus vaccine for use in adults |
| DTPa | diphtheria-tetanus-acellular pertussis vaccine |
| dTpa | diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation |
| DTPw | diphtheria-tetanus-whole-cell pertussis vaccine |
| EIA | enzyme immunoassay |
| ELISA | enzyme-linked immunosorbent assay |
| FHA | filamentous haemagglutinin |
| FIM | fimbriae (pertussis) |
| GBS | Guillain-Barré syndrome |
| GP | general practitioner |
| GVHD | graft-versus-host disease |
| HAV | hepatitis A virus |
| HBcAg | hepatitis B core antigen |
| HBeAg | hepatitis B e antigen |
| HBIG | hepatitis B immunoglobulin |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCW | healthcare worker |
| HDCV | human diploid cell vaccine (rabies) |
| HepA | hepatitis A vaccine |
| HepB | hepatitis B vaccine |
| HHE | hypotonic-hyporesponsive episode |
| Hib | Haemophilus influenzae type b |
| Hib-MenCCV | Haemophilus influenzae type b-meningococcal C conjugate vaccine |
| HIV | human immunodeficiency virus |
| HPV | human papillomavirus |
| HRIG | human rabies immunoglobulin |
| HSCT | haematopoietic stem cell transplant |
| HZ | herpes zoster |
| ID | intradermal |
| IgA/G/M | immunoglobulin A/G/M |
| IM | intramuscular |
| IPD | invasive pneumococcal disease |
| IPV | inactivated poliomyelitis vaccine |
| IS | intussusception |
| ITP | idiopathic thrombocytopenia purpura |
| IU | international units |
| IV | intravenous |
| IVIG | intravenous immunoglobulin |
| JE | Japanese encephalitis |
| LT-ETECheat | labile toxin producing enterotoxigenic Escherichia coli |
| MenCCV | meningococcal serogroup C conjugate vaccine |
| MMR | measles-mumps-rubella |
| MMRV | measles-mumps-rubella-varicella |
| NCIRS | National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases |
| NHIG | normal human immunoglobulin |
| NHMRC | National Health and Medical Research Council |
| NICC | National Immunisation Catch-up Calculator |
| NIP | National Immunisation Program The National Immunisation Program (NIP) was set up by the Commonwealth and state and territory governments in 1997. It aims to increase national immunisation coverage to reduce the number of cases of diseases that are preventable by vaccination in Australia. For more information visit the National Immunisation Program and the National Immunisation Program Schedule on health.gov.au. |
| NSW | New South Wales |
| NT | Northern Territory |
| NTHi | non-typeable Haemophilus influenzae |
| OMP | outer membrane protein |
| OPV | oral poliomyelitis vaccine |
| PCECV | purified chick embryo cell vaccine (rabies) |
| PCR | polymerase chain reaction |
| PCV | pneumococcal conjugate vaccine. |
Portable Document Format |
|
| PEP | post-exposure prophylaxis |
| pH1N1 | pandemic influenza A(H1N1)pdm09 |
| PHN | post-herpetic neuralgia |
| PI | product information |
| PreP | pre-exposure prophylaxis |
| PRN | pertactin |
| PRP | polyribosylribitol phosphate |
| PRP-OMP | PRP conjugated to the outer membrane protein of Neisseria meningitidis |
| PRP-T | PRP conjugated to tetanus toxoid |
| PT | pertussis toxoid |
| Qld | Queensland |
| RCT | randomised controlled trial |
| RIG | rabies immunoglobulin |
| RNA | ribonucleic acid |
| SA | South Australia |
| SC | subcutaneous |
| SCID | severe combined immunodeficiency |
| SIDS | sudden infant death syndrome |
| SOT | solid organ transplant |
| SSPE | subacute sclerosing panencephalitis |
| Tas | Tasmania |
| TB | tuberculosis |
| TCID50 | tissue culture infectious dose 50% |
| TGA | Therapeutic Goods Administration |
| TIG | tetanus immunoglobulin |
| TST | tuberculin skin test |
| Vic | Victoria |
| VLP | virus-like particle |
| VNAb | (rabies) virus neutralising antibody |
| VPD | vaccine-preventable disease |
| VV | varicella vaccine |
| VZV | varicella-zoster virus |
| WA | Western Australia |
| WHO | World Health Organization |
| ZIG | zoster immunoglobulin |